AIM: To evaluate the outcome of newly diagnosed anaplastic glioma patients treated in our institution in relation to the 2016 WHO classification suggestions. METHODS: This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria. RESULTS: 123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65.5, 21.2 and 21.2%; the 2, 3 and 5 years overall survival rate were 89.7, 83.0 and 58.4%. From the univariate/multivariate analysis, the factors conditioning survival were Karnofsky performance scale, extent of resection, IDH1 mutation status and presence of 1p/19q codeletion. CONCLUSION: The choice of adjuvant treatment have to consider molecular assessment and, in our experience, the extent of surgical resection.
AIM: To evaluate the outcome of newly diagnosed anaplastic gliomapatients treated in our institution in relation to the 2016 WHO classification suggestions. METHODS: This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria. RESULTS: 123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65.5, 21.2 and 21.2%; the 2, 3 and 5 years overall survival rate were 89.7, 83.0 and 58.4%. From the univariate/multivariate analysis, the factors conditioning survival were Karnofsky performance scale, extent of resection, IDH1 mutation status and presence of 1p/19q codeletion. CONCLUSION: The choice of adjuvant treatment have to consider molecular assessment and, in our experience, the extent of surgical resection.
Entities:
Keywords:
2016 WHO classification; anaplastic glioma; chemotherapy; multimodal approach; radiotherapy; surgery
Authors: Felix Sahm; David Reuss; Christian Koelsche; David Capper; Jens Schittenhelm; Stephanie Heim; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Wolf Mueller; Christian Hartmann; Werner Paulus; Andreas von Deimling Journal: Acta Neuropathol Date: 2014-08-21 Impact factor: 17.088
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Adriana Olar; Khalida M Wani; Kristin D Alfaro-Munoz; Lindsey E Heathcock; Hinke F van Thuijl; Mark R Gilbert; Terri S Armstrong; Erik P Sulman; Daniel P Cahill; Elizabeth Vera-Bolanos; Ying Yuan; Jaap C Reijneveld; Bauke Ylstra; Pieter Wesseling; Kenneth D Aldape Journal: Acta Neuropathol Date: 2015-02-21 Impact factor: 17.088
Authors: Marta Brell; Avelina Tortosa; Eugenia Verger; Juan Miguel Gil; Nuria Viñolas; Salvador Villá; Juan José Acebes; Lluis Caral; Teresa Pujol; Isidro Ferrer; Teresa Ribalta; Francesc Graus Journal: Clin Cancer Res Date: 2005-07-15 Impact factor: 12.531
Authors: Michael Weller; Wolfgang Wick; Ken Aldape; Michael Brada; Mitchell Berger; Stefan M Pfister; Ryo Nishikawa; Mark Rosenthal; Patrick Y Wen; Roger Stupp; Guido Reifenberger Journal: Nat Rev Dis Primers Date: 2015-07-16 Impact factor: 52.329
Authors: Benedikt Wiestler; David Capper; Martin Sill; David T W Jones; Volker Hovestadt; Dominik Sturm; Christian Koelsche; Anna Bertoni; Leonille Schweizer; Andrey Korshunov; Elisa K Weiß; Maximilian G Schliesser; Alexander Radbruch; Christel Herold-Mende; Patrick Roth; Andreas Unterberg; Christian Hartmann; Torsten Pietsch; Guido Reifenberger; Peter Lichter; Bernhard Radlwimmer; Michael Platten; Stefan M Pfister; Andreas von Deimling; Michael Weller; Wolfgang Wick Journal: Acta Neuropathol Date: 2014-07-10 Impact factor: 17.088
Authors: J S Frenel; C Leux; D Loussouarn; A-G Le Loupp; F Leclair; M Aumont; A Mervoyer; S Martin; M G Denis; M Campone Journal: J Neurooncol Date: 2013-05-17 Impact factor: 4.506